Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development.

about

Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development.

Item

http://www.wikidata.org/entity/Q36126047

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Targeted disruption of fibrino ...... ellular carcinoma development.

@ast

Targeted disruption of fibrino ...... ellular carcinoma development.

@en

type

Item

label

Targeted disruption of fibrino ...... ellular carcinoma development.

@ast

Targeted disruption of fibrino ...... ellular carcinoma development.

@en

prefLabel

Targeted disruption of fibrino ...... ellular carcinoma development.

@ast

Targeted disruption of fibrino ...... ellular carcinoma development.

@en

P1476

Targeted disruption of fibrino ...... ellular carcinoma development.

@en

P2093

Anal Desai

http://www.w3.org/2001/XMLSchema#string

Chinweike Ukomadu

http://www.w3.org/2001/XMLSchema#string

David E Cohen

http://www.w3.org/2001/XMLSchema#string

Hamed Nayeb-Hashemi

http://www.w3.org/2001/XMLSchema#string

Roderick T Bronson

http://www.w3.org/2001/XMLSchema#string

Valeriy Demchev

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and initial characterization of a novel fibrinogen-related gene, HFREP-1

Molecular cloning and functional expression analysis of a cDNA for human hepassocin, a liver-specific protein with hepatocyte mitogenic activity

LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma

Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization

Cloning and characterization of a novel RING-B-box-coiled-coil protein with apoptotic function

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

Pilot study: rapamycin in advanced hepatocellular carcinoma.

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice.

Liver growth in the embryo and during liver regeneration in zebrafish requires the cell cycle regulator, uhrf1

P304

167-173

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBRC.2015.07.078

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

465

http://www.w3.org/2001/XMLSchema#string

P50

Jason L. Hornick

P577

2015-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280584395

http://www.w3.org/2001/XMLSchema#string

P698

26225745

http://www.w3.org/2001/XMLSchema#string

P932

4594872

http://www.w3.org/2001/XMLSchema#string